Europe’s healthcare regulator has endorsed using dexamethasone to treat COVID-19 patients with breathing difficulties, paving the way for the steroid to become the region’s second approved treatment for the respiratory illness.
The European Medicines Agency (EMA) said on Friday the drug could be an option to treat adults and adolescents needing oxygen therapy or mechanical ventilation, after concluding its review of results from a trial by British scientists.
The study, dubbed RECOVERY, by researchers at the University of Oxford, showed in June that dexamethasone reduced death rates by about a third in severely ill, hospitalised COVID-19 patients. The drug has since been approved in Japan as a COVID-19 treatment.
Better late than never, we are almost in the third week of Sept. Given lives are at risk, I think they should have reacted a lot quicker than this. "University of Oxford, showed in June that Dexamethasone reduced death rates by about a third".
absolutely agree with that 2g! About flipping time. I wonder how many lives could have been saved.
My friend's husband has myeloma and is on regularchemo. He absolutely shouldn'thavegone but he caught C19 at Cheltenham Races last March and he absolutely should have died. His consultant is sure his survival was/is down to the dexamethosone and antiviral he was on. P
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.